Key Takeaways & Executive Findings
- •• High glucose upregulates ZIPK, STAT5A, p53, and NOS2 in HUVECs, leading to increased oxidative stress. • ZIPK interacts with STAT5A in the nucleus under high-glucose conditions, and silencing ZIPK or STAT5A reduces ROS accumulation and p53/NOS2 expression. • The ZIPK inhibitor TC-DAPK6 decreases ZIPK, p53, and NOS2 expression in diabetic rats, suggesting therapeutic potential. • ZIPK is a promising target for mitigating diabetic vascular complications via the STAT5A/p53/ROS pathway.
Abstract
In this study we investigate the role of Zipper-interacting protein kinase (ZIPK) in high glucose-induced vascular injury, focusing on its interaction with STAT5A and its effects on p53 and inducible nitric oxide synthase (NOS2) expression. Human umbilical vein endothelial cells (HUVECs) are cultured under normal (5 mM) and high (25 mM) glucose conditions. Protein and gene expression levels are assessed by western blot analysis and qPCR respectively, while ROS levels are measured via flow cytometry. ZIPK expression is manipulated using overexpression plasmids, siRNAs, and shRNAs. The effects of the ZIPK inhibitor TC-DAPK6 are evaluated in a diabetic rat model. Our results show that high glucose significantly upregulates ZIPK, STAT5A, p53, and NOS2 expressions in HUVECs, thus increasing oxidative stress. Silencing of STAT5A reduces p53 and NOS2 expressions and reactive oxygen species (ROS) accumulation. ZIPK is essential for high glucose-induced p53 expression and ROS accumulation, while silencing of ZIPK reverses these effects. Overexpression of ZIPK combined with STAT5A silencing attenuates glucose-induced alterations in p53 and NOS2 expression, thereby preventing cell damage. Coimmunoprecipitation reveals a direct interaction between ZIPK and STAT5A in the nucleus under high-glucose condition. In diabetic rats, TC-DAPK6 treatment significantly decreases ZIPK, p53, and NOS2 expressions. Our findings suggest that ZIPK plays a critical role in high glucose-induced vascular injury via STAT5A-mediated pathways, proposing that ZIPK is a potential therapeutic target for diabetic vascular complications.
1. Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia resulted from defects in insulin secretion, insulin action, or both. According to the International Diabetes Federation (IDF), approximately 463 million adults were living with diabetes in 2019, and this number is projected to increase to 700 million by 2045 [1]. This disease is associated with significant morbidity and mortality, with cardiovascular complications being the leading cause of death among diabetic patients [2]. Despite advancements in diabetes management, including lifestyle modifications, oral hypoglycemic agents, and insulin therapy, the prevention and treatment of diabetes-related vascular complications remain significant challenges [3,4].
Vascular complications in diabetes are primarily driven by endothelial dysfunction, which is exacerbated by hyperglycemia-induced oxidative stress and inflammation [5,6]. Endothelial cells, such as human umbilical vein endothelial cells (HUVECs), play a crucial role in maintaining vascular homeostasis. Hyperglycemia induces the production of reactive oxygen species (ROS) in endothelial cells, leading to cellular damage and apoptosis [7,8]. Furthermore, the dysregulation of various signaling pathways, including those involving protein kinases, is implicated in the pathogenesis of diabetic vascular complications [9,10].
Loading authentic research manuscript (Pages 1–5)...
Qichao Wu, Tingting Xie, Chang Fu, Chenyu Sun, Yan Ma, Zhengzhe Huang, Jiao Yang, Xiaoxiao Li, Wenqian Li, Changhong Miao (2026). ZIPK collaborates with STAT5A in p53-mediated ROS accumulation in hyperglycemia-induced vascular injury. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024120
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the role of ZIPK in hyperglycemia-induced vascular injury?
ZIPK is upregulated under high glucose conditions and collaborates with STAT5A to promote p53 expression and ROS accumulation, contributing to endothelial dysfunction and vascular injury.
How does ZIPK interact with STAT5A?
Coimmunoprecipitation reveals a direct interaction between ZIPK and STAT5A in the nucleus under high-glucose conditions, suggesting a coordinated transcriptional regulation.
What are the downstream effects of ZIPK/STAT5A pathway activation?
Activation leads to increased expression of p53 and NOS2, resulting in elevated ROS levels and oxidative stress, which are key drivers of diabetic vascular complications.
Can ZIPK be a therapeutic target for diabetic vascular complications?
Yes, the ZIPK inhibitor TC-DAPK6 significantly decreased ZIPK, p53, and NOS2 expression in diabetic rats, indicating that targeting ZIPK may offer a novel therapeutic strategy.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.